{
    "clinical_study": {
        "@rank": "164735", 
        "arm_group": [
            {
                "arm_group_label": "Vitrectomy with Aflibercept Injection", 
                "arm_group_type": "Active Comparator", 
                "description": "Preoperative 2.0mg intravitreal aflibercept and vitrectomy with intraoperative 2.0mg intravitreal aflibercept injection."
            }, 
            {
                "arm_group_label": "Standard Vitrectomy", 
                "arm_group_type": "Active Comparator", 
                "description": "Preoperative 2.0mg intravitreal aflibercept and standard of care vitrectomy."
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the ocular and systemic safety of intravitreal aflibercept injection in patients\n      undergoing Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy."
        }, 
        "brief_title": "Aflibercept Injection for Proliferative Diabetic Retinopathy", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Vitreous Hemorrhage", 
        "condition_browse": {
            "mesh_term": [
                "Diabetic Retinopathy", 
                "Hemorrhage", 
                "Retinal Diseases", 
                "Vitreous Hemorrhage"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients who need Pars Plana Vitrectomy surgery, and agree to participate in this study will\n      receive an injection of 2.0mg aflibercept 4 to 6 days before Vitrectomy surgery.  Half of\n      these patients will be randomized to receive another injection of 2.0mg aflibercept\n      immediately after their surgery.  Postoperative patient visits in this study will be at 1\n      day, and at weeks 1, 4, 16 and 24, and at any other times as deemed necessary by the\n      Investigator."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Ability to provide written informed consent and comply with study assessments for the\n             full duration of the study\n\n          -  Age > 18 years\n\n          -  Diagnosed with proliferative diabetic retinopathy (PDR) requiring pars plana\n             vitrectomy (PPV)\n\n          -  Best corrected visual acuity in the study eye between 20/40 to light perception (LP)\n             using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart\n\n        Exclusion Criteria:\n\n          -  Pregnancy (positive urine pregnancy test) or lactation\n\n          -  Premenopausal women not using adequate contraception.  The following are considered\n             effective means of contraception:  surgical sterilization or use of oral\n             contraceptives, barrier contraception with either a condom or diaphragm in\n             conjunction with spermicidal gel, an intrauterine device (IUD), or contraceptive\n             hormone implant or patch.\n\n          -  Participation in a study of an investigational drug or device within the past 30 days\n             prior to enrolling in the study\n\n          -  For previously treated subjects -\n\n          -  Prior treatment with anti-vascular endothelial growth factor (anti-VEGF) therapy in\n             the study eye within 28 days of Screening\n\n          -  Prior treatment with triamcinolone in the study eye within 6 months of Screening.\n\n          -  Prior treatment with dexamethasone in the study eye within 30 days of Screening\n\n          -  Intraocular surgery (including cataract surgery) in the study eye within 2 months\n             preceding Baseline\n\n          -  History of vitrectomy surgery, submacular surgery, or other surgical intervention for\n             PDR in the study eye\n\n          -  Active intraocular inflammation (grade trace or above) in the study eye\n\n          -  History of rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) in the\n             study eye\n\n          -  Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either\n             eye\n\n          -  Uncontrolled glaucoma in the study eye (defined as intraocular pressure (IOP) \u2265 30\n             mmHg despite treatment with anti-glaucoma medication)\n\n          -  History of cerebral vascular accident, myocardial infarction, transient ischemic\n             attacks within 6 months of study enrollment.\n\n          -  History of allergy to fluorescein, indocyanine green (ICG) or iodine, not amenable to\n             treatment\n\n          -  Presence of macular traction\n\n          -  Uncontrolled hypertension (e.g., 120/200 mmHg) prior to surgery (PPV)\n\n          -  Concomitant use of any systemic anti-VEGF therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01805297", 
            "org_study_id": "VS-12-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Vitrectomy with Aflibercept Injection", 
                "description": "One time 2.0mg aflibercept injection, following pars plana vitrectomy.", 
                "intervention_name": "Intravitreal Aflibercept Injection", 
                "intervention_type": "Drug", 
                "other_name": "Eylea"
            }, 
            {
                "arm_group_label": "Standard Vitrectomy", 
                "description": "Surgical intervention", 
                "intervention_name": "Standard Vitrectomy", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Proliferative Diabetic Retinopathy", 
        "lastchanged_date": "December 19, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Oklahoma City", 
                    "country": "United States", 
                    "state": "Oklahoma", 
                    "zip": "73104"
                }, 
                "name": "Dean McGee Eye Institute"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Intravitreal Aflibercept Injection as a Surgical Adjuvant in Severe Proliferative Diabetic Retinopathy", 
        "overall_official": [
            {
                "affiliation": "Dean McGee Eye Institute", 
                "last_name": "Robert E Leonard, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Dean McGee Eye Institute", 
                "last_name": "Vinay A Shah, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Rate and amount of post-operative vitreous hemorrhage.", 
            "safety_issue": "Yes", 
            "time_frame": "24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01805297"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Mean change in visual acuity", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Need for any additional surgical intervention.", 
                "safety_issue": "Yes", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Changes in mean central retinal thickness.", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "description": "Clinical findings secondary to vitreous hemorrhage, such as mean change in visual acuity, any additional surgical intervention, mean central retinal thickness, and", 
                "measure": "Changes in mean proliferative diabetic retinopathy (PDR) grading.", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }
        ], 
        "source": "University of Oklahoma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Oklahoma", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}